Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shannon Otsuka is active.

Publication


Featured researches published by Shannon Otsuka.


Journal of Thoracic Oncology | 2011

CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer

Shannon Otsuka; Alexander C. Klimowicz; Karen Kopciuk; Stephanie K. Petrillo; Mie Konno; Desiree Hao; Huong Muzik; Erin Stolte; William Boland; Don Morris; Anthony M. Magliocco; D. Gwyn Bebb

Background: It has been proposed that the chemokine receptor, CXCR4, and its ligand, stromal cell-derived factor-1 (SDF-1), play a critical role in organ-specific tumor metastasis. High CXCR4 expression in resected non-small cell lung cancer (NSCLC) tumors is associated with poorer outcome; however, its effect on patient outcome in advanced NSCLC has not been explored. Methods: After institutional ethical approval was obtained, demographic details, clinical variables, and outcome data were collected on consecutive NSCLC patients diagnosed at the Tom Baker Cancer Centre from 2003 to 2006 (Glans-Look Lung Cancer Database). Formalin-fixed paraffin-embedded diagnostic biopsies from stage IV patients were obtained and tissue microarrays generated. CXCR4 expression within NSCLC cells was analyzed by quantitative fluorescent immunohistochemistry using the HistoRx PM-2000 platform and then correlated with clinical outcome. Results: Of 832 patients, 170 had samples suitable for tissue microarray generation and analysis. Automated immunohistochemistry for CXCR4 was successfully completed on all 170 patients. High expressors had a significantly poorer median overall survival of 2.7 months versus 5.6 months for the low expressors (p = 0.0468). This difference is driven by high-expressing females who have a median overall survival of 1.6 months versus 6.4 months for the low expressors (p = 0.006). Conclusions: CXCR4 is expressed in the majority of NSCLC tumors, and overexpression is associated with significantly poorer survival in stage IV NSCLC patients. Interestingly, this poor outcome is disproportionately represented in the female population. Our results suggest a gender-dependent difference in clinical outcome based on CXCR4 overexpression in stage IV NSCLC.


Micron | 2014

Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architecture

Lik Hang Lee; Mauro Tambasco; Shannon Otsuka; Allison Wright; Alexander C. Klimowicz; Stephanie K. Petrillo; Don Morris; Anthony M. Magliocco; D. Gwyn Bebb

INTRODUCTION In recent years, differences have emerged in the treatment of squamous and non-squamous non-small cell lung carcinomas (NSCLCs). This highlights the importance of accurate histopathologic classification. However, there remains inter-observer disagreement when making diagnoses based on histology. Fractal dimension (FD) is a mathematical measure of irregularity and complexity of shape. We hypothesize that the FD of carcinoma epithelial architecture can assist in differentiating adenocarcinoma (ADC) from squamous cell carcinoma (SCC) of the lung. METHODS 134 resected (88 ADC and 46 SCC) cases of resected early-stage NSCLC were analyzed. Tissue micro arrays were generated from formalin-fixed paraffin-embedded tissue, stained with pan-cytokeratin, and digitally imaged and the FD of the epithelial structure calculated. Mean FD of ADC and SCC were compared using the independent t-test, partial correlations, and receiver operating characteristic (ROC) analyses. RESULTS A statistically significant difference (p<0.001) between the mean FD of ADC (M=1.70, SD=0.07) and SCC (M=1.78, SD=0.07) was found. Significance remained (p<0.001) when controlling for several possible confounders. ROC analysis demonstrated an area-under-the-curve of 0.81 (p<0.001). CONCLUSIONS The epithelial structure FD of NSCLC has potential as a reproducible and automated measure to help subtype NSCLCs into ADC and SCC. With further image analysis algorithm improvements, fractal analysis may be a component in computerized histomorphological assessments of lung cancer and may provide an adjunct test in differentiating NSCLCs.


Leukemia Research | 2010

Susceptibility of mantle cell lymphomas to reovirus oncolysis

Tommy Alain; Huong Muzik; Shannon Otsuka; Salina Chan; Tony Magliocco; Roman Diaz; Peter Forsyth; Don Morris; Gwyn Bebb

Mantle cell lymphoma (MCL) an incurable B-cell, non-Hodgkin lymphoma (NHL) urgently requires new treatments. We assessed reovirus mediated oncolysis in a panel of human MCL cell lines. In vitro, we found the cytopathic effect of reovirus infection ranged from high to very limited and correlated with levels of Ras activation. In vivo, a single reovirus injection intra-tumorally resulted in complete regression of both the injected and the contra-lateral tumor in a subcutaneous bi-tumor model, in one out of three cell lines tested. Reovirus treatment of MCL seems feasible but will need to be guided by the presence of molecular determinants of reovirus susceptibility.


Oncotarget | 2018

Cav3.1 overexpression is associated with negative characteristics and prognosis in non-small cell lung cancer

Aleksi Suo; Allison Childers; Adrijana D’Silva; Lars F. Petersen; Shannon Otsuka; Michelle Dean; Haocheng Li; Emeka K. Enwere; Brant Pohorelic; Alexander C. Klimowicz; Ivana A. Souza; Jawed Hamid; Gerald W. Zamponi; DGwyn Bebb

Introduction Voltage-gated calcium channels (VGCC) have been found to be differentially expressed in several different tumor types, but their role in tumor growth, malignant invasion, metastases and impact on clinical outcomes has not been clarified. Materials and Methods From a cohort database of 193 patients with early-stage NSCLC, 163 formalin-fixed paraffin-embedded specimens were available for analysis to construct tissue microarrays. Cav3.1 protein expression was detected using fluorescence immunohistochemistry, and quantified using automated image acquisition and analysis. Results Among the cohort of 193 NSCLC patients, adenocarcinoma (53.9%) and squamous cell carcinoma (SCC) (30.1%) were the most common histologies. There was no difference between SCC and non-SCC subtypes in overall survival (OS) or relapse-free survival (RFS); 74.2 vs 90.1 months (p = 0.543) and 48.8 vs 52.6 months (p = 0.766), respectively. T-type VGCC 3.1 (Cav3.1) overexpression was assessed by tissue microarray immunohistochemistry analysis from 163 available patient samples. Eighteen (11.0%) NSCLC primaries were found to have Cav3.1 overexpression levels, and were significantly associated with SCC histology (p < 0.001), larger tumor size (p < 0.001) and later stage disease at diagnosis (p = 0.019). Median OS was 48.6 vs 106.7 months for Cav3.1 overexpressing and non-overexpressing patients, respectively (p = 0.032). Regression analysis revealed a significantly negative effect for Cav3.1 overexpression on RFS (Hazard ratio [HR] = 2.02, p = 0.048). Conclusions Cav3.1 overexpression is a potential biomarker for poorer patient outcomes. These results bring supportive evidence for calcium channels inducing an aggressive phenotype in NSCLC and potentially may serve as a therapeutic target in overexpressing tumors.


Oncotarget | 2017

Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC

Lars F. Petersen; Alexander C. Klimowicz; Shannon Otsuka; A. Elegbede; Stephanie K. Petrillo; Tyler Williamson; Chris T. Williamson; Mie Konno; Susan P. Lees-Miller; Desiree Hao; Don Morris; Anthony M. Magliocco; D. Gwyn Bebb

Ataxia-telangiectasia mutated (ATM) is critical in maintaining genomic integrity. In response to DNA double-strand breaks, ATM phosphorylates downstream proteins involved in cell-cycle checkpoint arrest, DNA repair, and apoptosis. Here we investigate the frequency, and influence of ATM deficiency on outcome, in early-resected non-small cell lung cancer (NSCLC). Tissue microarrays, containing 165 formalin-fixed, paraffin-embedded resected NSCLC tumours from patients diagnosed at the Tom Baker Cancer Centre, Calgary, Canada, between 2003 and 2006, were analyzed for ATM expression using quantitative fluorescence immunohistochemistry. Both malignant cell-specific ATM expression and the ratio of ATM expression within malignant tumour cells compared to that in the surrounding tumour stroma, defined as the ATM expression index (ATM-EI), were measured and correlated with clinical outcome. ATM loss was identified in 21.8% of patients, and was unaffected by clinical pathological variables. Patients with low ATM-EI tumours had worse survival outcomes compared to those with high ATM-EI (p < 0.01). This effect was pronounced in stage II/III patients, even after adjusting for other clinical co-variates (p < 0.001). Additionally, we provide evidence that ATM-deficient patients may derive greater benefit from guideline-recommended adjuvant chemotherapy following surgical resection. Taken together, these results indicate that ATM loss seems to be an early event in NSCLC carcinogenesis and is an independent prognostic factor associated with worse survival in stage II/III patients.


American Journal of Clinical Oncology | 2018

Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non–Small Cell Lung Cancer

Amanda Williams Gibson; Haocheng Li; Adrijana D’Silva; R. Tudor; A. Elegbede; Shannon Otsuka; Dafydd Gwyn Bebb; Winson Y. Cheung


Journal of Clinical Oncology | 2017

Referral to a cancer center (CC), medical oncologist (MO), and use of systemic treatment (ST) in stage IV non-small cell lung cancer (NSCLC) patients: Comparison of years 2003-2006 and 2010 cohorts in a single Canadian institution.

Jenny J. Ko; Mingfu Liu; Shannon Otsuka; William Boland; Kate Skolnik; James Macklow; Donald Morris; D. Gwyn Bebb


Radiotherapy and Oncology | 2016

163: Cumulative Incidence of Brain Metastasis after Diagnosis of Non-Small Cell Lung Cancer: Estimates from a Regional Cancer Centre Cohort

A. D'Silva; Shannon Otsuka; Haocheng Li; Jackson Wu; Don Morris; Gwyn Bebb


Annals of Oncology | 2016

Reaching the pinnacle of stage III NSCLC treatment

A. D'Silva; H. Lau; Shannon Otsuka; R. Tudor; D.G. Bebb


Annals of Oncology | 2013

P04.14POTENTIAL THERAPEUTIC IMPLICATIONS OF ALTERED ATM AND P53 STATUS IN SOLID TUMOURS

D. G. Bebb; A. A. Elegbede; E. Kubota; L. F. Petersen; Shannon Otsuka; Susan P. Lees-Miller

Collaboration


Dive into the Shannon Otsuka's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

D. Gwyn Bebb

Tom Baker Cancer Centre

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Desiree Hao

Tom Baker Cancer Centre

View shared research outputs
Top Co-Authors

Avatar

Gwyn Bebb

Tom Baker Cancer Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge